Encouraging real-world CV safety profile for rhGH in Noonan syndrome
Treatment with recombinant human growth hormone is not associated with cardiovascular adverse events in clinical practice, show data from two large, multicentre cohorts.
Treatment with recombinant human growth hormone is not associated with cardiovascular adverse events in clinical practice, show data from two large, multicentre cohorts.
Young children with short stature due to aggrecan deficiency achieve a marked improvement in height velocity during their first year of treatment with recombinant human growth hormone, shows a cohort study.
The likelihood of finding an underlying genetic cause of short stature in children is markedly increased if they have additional factors such as dysmorphic facial features or skeletal dysplasia, say researchers.
Recombinant human growth hormone appears to have a positive effect on growth in children with Kabuki Syndrome, shows an open-label study.
Programme Director Professor Martin Savage is joined by experts to present and discuss the application of precision medicine in endocrine disorders, offering clinical expertise and insight, evidence and opinion on this topic.
Children with Cushing’s disease who have a negative magnetic resonance imaging pituitary scan are less likely to achieve remission after surgery than those with a confirmed tumour, say researchers.
A phase 2 study of macimorelin in children with suspected growth hormone deficiency shows similar results to those established in adults.
Findings from the PATRO Children study support the use of a biosimilar formulation of recombinant human growth hormone (somatropin) in children with Turner’s syndrome.
Researchers have found a large variety of genetic diagnoses in children with short stature investigated for suspected growth hormone insensitivity.
Researchers find that teenagers with endocrine disorders often have gaps in their knowledge of their condition and how to manage it, making them poorly prepared for transition to adult clinic.